The Evaluation of Favipiravir Utilization and Clinical Outcome of Inpatients Covid-19 in Secondary Care Hospital, Central Java

IF 0.7 Q4 PHARMACOLOGY & PHARMACY
Nialiana Endah Endriastuti, Heny Ekowati, Masita Wulandari Suryoputri
{"title":"The Evaluation of Favipiravir Utilization and Clinical Outcome of Inpatients Covid-19 in Secondary Care Hospital, Central Java","authors":"Nialiana Endah Endriastuti, Heny Ekowati, Masita Wulandari Suryoputri","doi":"10.22146/ijp.5274","DOIUrl":null,"url":null,"abstract":"Coronavirus Disease 2019 (COVID-19) is a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The favipiravir is one of the antiviral treatments for COVID-19. There has been limited research done on favipiravir in Indonesia, and there is controversy on the drug's efficacy. This study aims to determine the utilization of favipiravir affected patients with COVID-19. This study was a retrospective data collection method and an observational study. The information was collected from the medical reports of confirmed COVID-19 patients between in March 2020 and June 2021 at the Secondary Care Hospital in Banyumas Regency, Central Java Province, Indonesia. By comparing clinical symptoms before and after using favipiravir, the results of temperature, respiratory rate, and cough symptom parameters were used to evaluate the effects of using favipiravir on clinical symptoms. The total number of 250 patients were qualified the inclusion criteria consisted of 90 patients with severity of illness in mild level, 101 patients had moderate level, and 59 patients with severe level. Most patients reported symptoms of coughing, shortness of breath, weakness, fever, and nausea. The majority of favipiravir patients (n=200; 80%) initiated with a dose of 1600 mg/12 hours, followed by a dose of 600 mg/12 hours, with the longest length of therapy (8-14 days) (n=145; 58%). At all grades of disease severity, statistical analysis of patients showed the significant improvement in cough, fever, and respiratory rate after taking favipiravir (p=0.0001). In conclusion, favipiravir may have beneficial effects on COVID-19 patients in all grade severity of illness.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":"53 1","pages":"0"},"PeriodicalIF":0.7000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INDONESIAN JOURNAL OF PHARMACY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/ijp.5274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Coronavirus Disease 2019 (COVID-19) is a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The favipiravir is one of the antiviral treatments for COVID-19. There has been limited research done on favipiravir in Indonesia, and there is controversy on the drug's efficacy. This study aims to determine the utilization of favipiravir affected patients with COVID-19. This study was a retrospective data collection method and an observational study. The information was collected from the medical reports of confirmed COVID-19 patients between in March 2020 and June 2021 at the Secondary Care Hospital in Banyumas Regency, Central Java Province, Indonesia. By comparing clinical symptoms before and after using favipiravir, the results of temperature, respiratory rate, and cough symptom parameters were used to evaluate the effects of using favipiravir on clinical symptoms. The total number of 250 patients were qualified the inclusion criteria consisted of 90 patients with severity of illness in mild level, 101 patients had moderate level, and 59 patients with severe level. Most patients reported symptoms of coughing, shortness of breath, weakness, fever, and nausea. The majority of favipiravir patients (n=200; 80%) initiated with a dose of 1600 mg/12 hours, followed by a dose of 600 mg/12 hours, with the longest length of therapy (8-14 days) (n=145; 58%). At all grades of disease severity, statistical analysis of patients showed the significant improvement in cough, fever, and respiratory rate after taking favipiravir (p=0.0001). In conclusion, favipiravir may have beneficial effects on COVID-19 patients in all grade severity of illness.
中爪哇省二级医院新冠肺炎住院患者Favipiravir使用及临床疗效评价
2019冠状病毒病(COVID-19)是一种由严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)引起的疾病。favipiravir是COVID-19的抗病毒治疗药物之一。在印度尼西亚,对favipiravir进行的研究有限,而且对这种药物的疗效也存在争议。本研究旨在确定COVID-19患者对法匹拉韦的使用情况。本研究采用回顾性资料收集法和观察性研究。这些信息收集自印度尼西亚中爪哇省Banyumas Regency二级保健医院2020年3月至2021年6月期间确诊的COVID-19患者的医疗报告。通过比较使用法匹拉韦前后的临床症状,通过体温、呼吸频率、咳嗽症状等参数评价使用法匹拉韦对临床症状的影响。共纳入250例患者,其中病情严重程度为轻度90例,中度101例,重度59例。大多数患者报告的症状为咳嗽、呼吸短促、虚弱、发烧和恶心。大多数favipiravir患者(n=200;80%),开始剂量为1600 mg/12小时,随后剂量为600 mg/12小时,最长治疗时间(8-14天)(n=145;58%)。在所有疾病严重程度级别,患者的统计分析显示,服用favipiravir后咳嗽、发烧和呼吸频率均有显著改善(p=0.0001)。总之,favipiravir可能对所有严重程度的COVID-19患者都有有益的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
INDONESIAN JOURNAL OF PHARMACY
INDONESIAN JOURNAL OF PHARMACY PHARMACOLOGY & PHARMACY-
CiteScore
1.20
自引率
0.00%
发文量
38
审稿时长
12 weeks
期刊介绍: The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信